Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 455.96% from the stock’s previous close.

A number of other brokerages also recently weighed in on CAPR. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Piper Sandler assumed coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Up 0.4 %

NASDAQ CAPR traded up $0.05 on Thursday, reaching $13.85. The company had a trading volume of 303,282 shares, compared to its average volume of 1,189,616. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The stock’s 50 day moving average is $16.95 and its 200-day moving average is $10.78. The stock has a market cap of $629.76 million, a price-to-earnings ratio of -13.07 and a beta of 3.98.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $426,000. State Street Corp lifted its position in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Capricor Therapeutics during the third quarter worth $3,806,000. Finally, The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics in the third quarter valued at $161,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.